FDA warns LyfeUnit website for selling unapproved, misbranded ketamine vials to U.S. consumers.
What happened
FDA reviewed www.lyfeunit.com on February 27, 2026, and found it offering ketamine 500mg/10ml vials marketed as “Mental Health Treatments.” FDA said the product is an unapproved new drug and is misbranded because its labeling lacks adequate directions for use and it is offered without a prescription.
What FDA found
The website sold ketamine 500mg/10ml vials without an FDA-approved drug application.
FD&C Act sections 301(d) and 505(a) (21 U.S.C. 331(d), 355(a))The ketamine product's labeling did not give adequate directions for safe use by a layperson.
FD&C Act section 502(f)(1) (21 U.S.C. 352(f)(1))The website offered a prescription drug without requiring a prescription from a licensed practitioner.
FD&C Act sections 503(b)(1) and 301(k) (21 U.S.C. 353(b)(1), 331(k))The website introduced misbranded drugs into interstate commerce.
FD&C Act section 301(a) (21 U.S.C. 331(a))
What FDA wants
FDA asks LyfeUnit to stop offering any unapproved and misbranded drugs for sale to U.S. consumers and to respond within 15 business days with corrective steps, preventive steps, and supporting documents.
Who should pay attention
- online sellers of ketamine or psychiatric drugs
- telehealth and mental health platforms that mention ketamine
- buyers and importers of foreign-labeled injectable drugs
This is a summary. Read the original letter on fda.gov.